📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Torrent Pharma Q3 Net Profit Rises 19% to ₹577 Cr; Declares ₹29 Interim Dividend
Torrent Pharmaceuticals reported a strong performance for Q3 FY2025-26, with net profit increasing 19% year-on-year to ₹577 crores. Revenue from operations grew to ₹2,599 crores compared to ₹2,377 crores in the same quarter last year. The company's board declared a substantial interim dividend of ₹29 per share (580% of face value), with a payout expected by March 6, 2026. For the nine-month period, the company has shown consistent growth, with total profit reaching ₹1,725 crores against ₹1,414 crores in the previous year.
Key Highlights
Net profit for Q3 FY26 rose 19% YoY to ₹577 crores from ₹485 crores.
Revenue from operations increased to ₹2,599 crores, up from ₹2,377 crores in Q3 FY25.
Declared an interim dividend of ₹29 per equity share (580% of face value).
Earnings Per Share (EPS) for the quarter improved to ₹17.04 from ₹14.33 YoY.
Nine-month total income grew to ₹7,937 crores compared to ₹7,266 crores in the prior year period.
💼 Action for Investors
Investors should consider the strong bottom-line growth and healthy dividend payout as positive indicators of operational efficiency. The stock remains a robust pick for those seeking a combination of growth and regular income.
Torrent Pharma Q3 Net Profit Rises 19% to ₹577 Cr; Declares ₹29 Interim Dividend
Torrent Pharmaceuticals reported a strong performance for Q3 FY26, with revenue from operations growing to ₹2,599 crore compared to ₹2,377 crore in the same quarter last year. Net profit saw a significant jump of approximately 19% year-on-year, reaching ₹577 crore. The company also announced a substantial interim dividend of ₹29 per equity share, representing 580% of the face value. For the nine-month period ended December 2025, the company maintained momentum with a net profit of ₹1,725 crore against ₹1,414 crore in the previous year.
Key Highlights
Revenue from operations increased by 9.3% YoY to ₹2,599 crore in Q3 FY26
Net profit for the quarter grew by 19% YoY to ₹577 crore from ₹485 crore
Board declared an interim dividend of ₹29 per share (580%) with payment expected by March 6, 2026
Basic and Diluted EPS improved to ₹17.04 for the quarter compared to ₹14.33 in the previous year's quarter
9M FY26 net profit stands at ₹1,725 crore, showing a robust 22% growth over 9M FY25
💼 Action for Investors
Investors should view the consistent double-digit profit growth and high dividend payout as a sign of strong operational health. The stock remains a solid hold for long-term investors looking for steady earnings growth and dividend income.
Torrent Pharma Q3 FY26 Revenue Grows 18% YoY to Rs 3,303 Crore
Torrent Pharmaceuticals reported a strong 18% year-on-year growth in total revenue for Q3 FY26, reaching Rs 3,303 crore compared to Rs 2,809 crore in the previous year. The growth was broad-based across all geographies, with the Brazil market leading at 27% growth and the US market growing by 19%. The core India business, which remains the largest contributor, grew by 14% to Rs 1,798 crore. For the nine-month period ending December 2025, the company achieved a total revenue of Rs 9,783 crore, marking a 14% increase over the same period last year.
Key Highlights
Total Q3 FY26 revenue increased 18% YoY to Rs 3,303 crore from Rs 2,809 crore
Brazil business recorded the highest regional growth of 27% YoY, reaching Rs 371 crore
India domestic revenue grew 14% YoY to Rs 1,798 crore, maintaining its dominant share
US revenue saw a significant 19% YoY increase to Rs 321 crore
YTD Dec 25 total revenue stands at Rs 9,783 crore, up 14% from Rs 8,557 crore in YTD Dec 24
💼 Action for Investors
Investors should take note of the robust double-digit growth across all major markets, indicating strong operational momentum. The stock remains a key pick in the pharma sector due to its high domestic exposure and improving international performance.
Torrent Pharma Declares ₹29 Interim Dividend; Q3 Net Profit Rises 19% YoY to ₹577 Cr
Torrent Pharmaceuticals has declared an interim dividend of ₹29 per share (580% of face value) for FY 2025-26. The company reported a strong Q3 FY26 performance with net profit rising 19% year-on-year to ₹577 crores, up from ₹485 crores in the same quarter last year. Revenue for the quarter grew to ₹2,599 crores, reflecting steady operational growth. The dividend is expected to be paid to shareholders on or around March 6, 2026.
Key Highlights
Declared an interim dividend of ₹29 per equity share of ₹5 face value
Q3 FY26 Net Profit grew 19% YoY to ₹577 crores vs ₹485 crores in Q3 FY25
Total Revenue from operations for Q3 FY26 rose to ₹2,599 crores from ₹2,377 crores YoY
Nine-month (9M FY26) Net Profit reached ₹1,725 crores compared to ₹1,414 crores in 9M FY25
Dividend payment is scheduled to be dispatched on or around March 6, 2026
💼 Action for Investors
Investors should consider the healthy dividend payout and double-digit profit growth as a sign of strong cash flow and operational stability. The stock remains a solid pick for long-term portfolios seeking a mix of growth and regular income.
Torrent Pharma Q3 Net Profit Rises 19% to ₹577 Cr; Declares ₹29 Interim Dividend
Torrent Pharmaceuticals reported a solid performance for Q3 FY26, with revenue from operations growing 9.3% year-on-year to ₹2,599 crore. Net profit saw a significant jump of 19%, reaching ₹577 crore compared to ₹485 crore in the same quarter last year. The board has rewarded shareholders with a substantial interim dividend of ₹29 per equity share. Despite a slight sequential dip in revenue compared to Q2 FY26, the year-to-date profit growth remains robust at 22%.
Key Highlights
Revenue from operations increased to ₹2,599 crore, up 9.3% YoY from ₹2,377 crore.
Net Profit for the quarter stood at ₹577 crore, representing a 19% YoY growth.
Interim dividend of ₹29 per share (580%) announced with a payment date around March 6, 2026.
Nine-month FY26 net profit reached ₹1,725 crore, a 22% increase over the previous year's ₹1,414 crore.
Basic EPS improved to ₹17.04 for the quarter from ₹14.33 in the year-ago period.
💼 Action for Investors
Investors should find the strong double-digit profit growth and high dividend payout encouraging, reflecting healthy cash flows. The stock remains a solid pick for those seeking stability in the domestic-focused pharmaceutical space.
Torrent Pharma Declares ₹29 Interim Dividend; Q3 Net Profit Rises 19% YoY to ₹577 Cr
Torrent Pharmaceuticals has declared a substantial interim dividend of ₹29 per equity share (580% of face value) for the financial year 2025-26. The company reported a strong Q3 performance with standalone net profit rising 19% year-on-year to ₹577 crore, driven by a 9.3% growth in total revenue to ₹2,599 crore. For the nine-month period ended December 2025, the company's net profit saw a significant 22% increase to ₹1,725 crore. The dividend is expected to be paid to shareholders on or around March 6, 2026.
Key Highlights
Declared an interim dividend of ₹29 per equity share of ₹5 each (580% payout)
Standalone Q3 net profit increased by 19% YoY to ₹577 crore from ₹485 crore
Total revenue for Q3 FY26 grew to ₹2,599 crore compared to ₹2,377 crore in Q3 FY25
9-month standalone net profit reached ₹1,725 crore, up from ₹1,414 crore in the previous year
Dividend payment or dispatch is scheduled to be completed by March 6, 2026
💼 Action for Investors
Investors should maintain a positive outlook given the strong 19% profit growth and healthy dividend payout. The stock remains attractive for long-term investors seeking consistent yield and steady earnings expansion in the pharmaceutical sector.
Torrent Pharma Completes JB Chemicals Stake Acquisition, Reaches 48.80% Holding
Torrent Pharmaceuticals has successfully completed its planned acquisition of J.B. Chemicals & Pharmaceuticals Limited shares. On February 3, 2026, the company acquired a final tranche of 92,490 shares (0.06%) from an employee, fulfilling all obligations under the Share Purchase Agreements dated June and July 2025. Following this transaction, Torrent Pharma's total stake in JB Chemicals stands at 48.80%, representing 7,83,57,892 equity shares. This marks the conclusion of a major strategic investment process initiated in 2025.
Key Highlights
Acquired 92,490 equity shares (0.06% stake) from a JB Chemicals employee on February 3, 2026
Total aggregate holding in JB Chemicals reached 7,83,57,892 equity shares
Final ownership stake stands at 48.80% of JB Chemicals on a fully diluted basis
Completion of all acquisitions under the Share Purchase Agreements dated June 29 and July 3, 2025
💼 Action for Investors
Investors should view this as a significant strategic consolidation that strengthens Torrent's market position; focus on upcoming quarterly results to see the impact of JB Chemicals' integration on the consolidated bottom line.
Torrent Pharma Sets Feb 19, 2026, as Record Date for Interim Dividend
Torrent Pharmaceuticals has fixed February 19, 2026, as the record date to determine shareholder eligibility for a potential interim dividend. The formal declaration of this dividend is subject to approval at the Board of Directors meeting scheduled for February 13, 2026. This announcement pertains to equity shares with a face value of ₹5 each. Investors holding the stock on the record date will be entitled to the payout if approved.
Key Highlights
Record date for interim dividend eligibility is Thursday, February 19, 2026.
Board meeting to consider and declare the dividend is scheduled for February 13, 2026.
The dividend applies to equity shares with a face value of ₹5 per share.
The notification is issued under Regulation 42 of SEBI Listing Regulations.
💼 Action for Investors
Investors seeking to receive the dividend should ensure they purchase or hold shares before the ex-dividend date. Monitor the February 13 board meeting outcome for the specific dividend amount per share.
Torrent Pharma's Dahej Facility Clears USFDA Inspection with Zero Observations
Torrent Pharmaceuticals has announced the successful conclusion of a USFDA inspection at its Dahej manufacturing facility. The audit took place from January 19 to January 23, 2026, and resulted in zero observations. This clean report signifies full compliance with global manufacturing standards and removes potential regulatory hurdles for the site. Such outcomes are critical for pharmaceutical companies to maintain and expand their product portfolio in the lucrative US market.
Key Highlights
USFDA inspection of the Dahej facility concluded on January 23, 2026
The audit resulted in zero observations, meaning no Form 483 was issued
Inspection period spanned five days from January 19 to January 23, 2026
Successful clearance ensures continued compliance for exports to the US market
💼 Action for Investors
This is a significant positive development that de-risks the company's US-led growth strategy. Investors should maintain confidence in the company's manufacturing quality and regulatory standing.
Torrent Pharma's Dahej Facility Clears USFDA Inspection with Zero Observations
Torrent Pharmaceuticals has successfully completed a USFDA inspection at its Dahej manufacturing facility. The inspection, which took place from January 19 to January 23, 2026, concluded with zero observations. This clean report indicates full compliance with international manufacturing standards and removes potential regulatory bottlenecks for the US market. Such an outcome is highly favorable for the company's export growth and future product approvals.
Key Highlights
USFDA inspection conducted at the Dahej facility from 19-Jan-26 to 23-Jan-26.
The inspection concluded with zero observations, meaning no Form 483 was issued.
Successful audit ensures continued compliance for the company's US-bound exports.
The clean report de-risks the facility from potential import alerts or warning letters.
💼 Action for Investors
This is a significant positive development that reduces regulatory risk; investors should maintain a positive outlook on the stock as it clears the path for new product launches in the US.
Torrent Pharma Completes Acquisition of 46.39% Stake in J.B. Chemicals
Torrent Pharmaceuticals has successfully completed the acquisition of a 46.39% stake in J.B. Chemicals & Pharmaceuticals Limited, totaling 7,44,82,836 equity shares. The acquisition was primarily executed through a share purchase agreement with Tau Investment Holdings Pte. Ltd. and supplemented by an open offer. Consequently, Torrent Pharma has assumed control of J.B. Chemicals and is now officially classified as its promoter effective January 21, 2026. This move marks a significant consolidation in the Indian pharmaceutical space, bringing a major domestic player under Torrent's umbrella.
Key Highlights
Acquired 7,44,81,519 shares (46.39% stake) from Tau Investment Holdings Pte. Ltd.
Total holding stands at 7,44,82,836 shares including 1,317 shares from the open offer.
Torrent Pharma is now the official 'promoter' of J.B. Chemicals as of January 21, 2026.
The transaction completes a process initiated via a share purchase agreement dated June 29, 2025.
💼 Action for Investors
Investors should view this as a major strategic expansion that strengthens Torrent's domestic portfolio and market share. Monitor the upcoming consolidated financial statements to evaluate the synergy benefits and the impact of acquisition debt on the balance sheet.
Torrent Pharma Allots NCDs Worth INR 10,990 Crore Across Four Series
Torrent Pharmaceuticals has successfully allotted 10.99 lakh Non-Convertible Debentures (NCDs) to raise a total of INR 10,990 crore through private placement. The fundraise is structured into four series with tenures ranging from 2 to 5 years and coupon rates between 7.45% and 7.80% per annum. These are senior, secured instruments backed by specified trademarks and designated accounts with a 1.1x security cover. This significant capital infusion is likely intended for refinancing existing debt or funding strategic growth initiatives.
Key Highlights
Total allotment of 10,99,000 NCDs aggregating to INR 10,990 crore via private placement
Four series issued with coupon rates ranging from 7.45% for 2-year tenure to 7.80% for 5-year tenure
Instruments are secured by a first ranking exclusive charge on specified trademarks with a 1.1x cover
Redemption dates are staggered across January 2028, 2029, 2030, and 2031
Subscription amounts received for Series 4 reached INR 3,504.51 crore against a nominal value of INR 3,500 crore
💼 Action for Investors
Investors should monitor the company's debt-to-equity ratio and the specific end-use of these funds, as such large-scale borrowing typically precedes major acquisitions or significant debt restructuring. The competitive interest rates obtained suggest strong institutional confidence in the company's credit profile.
Torrent Pharma Allots NCDs Worth ₹10,990 Crore Across Four Series
Torrent Pharmaceuticals has approved the allotment of Senior, Secured, Redeemable Non-Convertible Debentures (NCDs) totaling approximately ₹10,990 crore via private placement. The issuance is spread across four series with tenures ranging from 2 to 5 years and annual coupon rates between 7.45% and 7.80%. These securities are backed by a 1.1x security cover involving specified trademarks and designated accounts. This significant capital raise is likely aimed at refinancing existing debt or supporting large-scale strategic initiatives.
Key Highlights
Total fundraise of ₹10,990 crore through four distinct series of NCDs.
Coupon rates range from 7.45% for the 2-year series to 7.80% for the 5-year series.
Series 4 is the largest tranche, raising ₹3,500 crore with a maturity date of January 17, 2031.
The NCDs are secured by a first ranking exclusive charge over specified trademarks and designated accounts with 1.1x cover.
Allotment completed on January 19, 2026, with listing proposed on the NSE Wholesale Debt Market.
💼 Action for Investors
Investors should monitor the company's upcoming quarterly calls for clarity on the specific utilization of these funds, particularly regarding potential M&A or debt restructuring. The competitive interest rates reflect the company's strong credit profile in the debt market.
ICRA Reaffirms Torrent Pharma's Credit Ratings at [ICRA] AA+ (Stable) and [ICRA] A1+
ICRA Limited has reaffirmed Torrent Pharmaceuticals' long-term credit rating for its banking facilities and Non-Convertible Debentures (NCDs) at [ICRA] AA+ with a stable outlook. The short-term rating for the company's commercial paper programme has also been reaffirmed at [ICRA] A1+. Furthermore, the [ICRA] A1+ rating was assigned to an enhanced amount within the commercial paper programme. These ratings indicate a high degree of safety regarding timely servicing of financial obligations and very low credit risk.
Key Highlights
Long-term rating for banking facilities and NCDs reaffirmed at [ICRA] AA+ with a Stable outlook
Short-term rating for commercial paper programme reaffirmed at [ICRA] A1+
New [ICRA] A1+ rating assigned to an enhanced limit of the commercial paper programme
Ratings reflect the company's strong financial profile and robust creditworthiness
💼 Action for Investors
The reaffirmation of high credit ratings confirms the company's financial stability and low default risk; investors should maintain their positions as the credit profile remains strong.
Torrent Pharma to Raise up to ₹12,500 Crore via Non-Convertible Debentures (NCDs)
Torrent Pharmaceuticals has approved a massive fundraise of up to ₹12,500 crore through the issuance of Secured, Rated, Listed, Redeemable Non-Convertible Debentures (NCDs). The issuance will be conducted in one or more tranches on a private placement basis. The NCDs are secured by a 1.1x cover on specified trademarks and designated accounts. This significant capital raise is likely intended for strategic purposes, such as large-scale acquisitions or refinancing existing debt.
Key Highlights
Approved issuance of NCDs aggregating up to ₹12,500 crore in one or more tranches.
Proposed issuance of up to 12,50,000 NCDs with a face value of ₹1,00,000 each.
Securities will be listed on the Wholesale Debt Market Segment of the National Stock Exchange (NSE).
Security includes a first ranking exclusive charge over specified trademarks with a minimum cover of 1.1x.
Coupon rates and specific maturity dates will be determined at the time of allotment.
💼 Action for Investors
Investors should monitor the company's next steps as a fundraise of this magnitude often signals a major acquisition or significant expansion. Watch for the final coupon rates to understand the impact on the company's interest expense and debt-to-equity ratio.
Torrent Pharma to Raise Up to ₹12,500 Crore via Non-Convertible Debentures (NCDs)
Torrent Pharmaceuticals has approved a massive fundraise of up to ₹12,500 crore through the issuance of Secured, Rated, Listed, Redeemable Non-Convertible Debentures (NCDs). The issuance will be conducted on a private placement basis in one or more tranches and will be listed on the NSE Wholesale Debt Market. The NCDs are backed by a 1.1x security cover involving specified trademarks and designated accounts. This significant capital raise points toward potential large-scale refinancing or upcoming inorganic growth opportunities.
Key Highlights
Approved issuance of NCDs aggregating up to ₹12,500 crore via private placement.
Proposed issuance of up to 12,50,000 NCDs with a face value of ₹1,00,000 each.
Security provided includes a first ranking exclusive charge over specified trademarks with a 1.1x cover.
The instruments will be listed on the Wholesale Debt Market Segment of the National Stock Exchange of India.
💼 Action for Investors
Investors should monitor the specific end-use of these funds, as a raise of this magnitude often precedes a major acquisition or significant debt restructuring. Keep an eye on the company's leverage ratios and interest coverage once the coupon rates are finalized.
Torrent Pharma Credit Rating Affirmed at IND AA+ (Stable); New CP Rated IND A1+
India Ratings and Research has reaffirmed Torrent Pharmaceuticals' credit rating for its existing banking facilities and Non-Convertible Debentures (NCDs) at IND AA+ with a stable outlook. Additionally, the agency has assigned a top-tier rating of IND A1+ for the company's proposed Commercial Paper program. These ratings reflect the company's strong financial profile and high creditworthiness within the pharmaceutical sector. The stable outlook suggests that the agency expects the company to maintain its credit profile in the medium term.
Key Highlights
India Ratings affirmed the existing issuer rating and NCDs at IND AA+ with a Stable outlook
A new credit rating of IND A1+ was assigned to the company's proposed Commercial Paper program
The affirmation covers all existing banking facilities, ensuring continued access to capital at competitive rates
The IND AA+ rating signifies a very high degree of safety regarding timely servicing of financial obligations
The assignment of IND A1+ for Commercial Paper indicates the highest degree of safety for short-term debt
💼 Action for Investors
Investors should view this as a confirmation of the company's financial stability and disciplined balance sheet management. The high credit ratings will help the company maintain low borrowing costs for its future expansion or working capital needs.
Torrent Pharma acquires 1,317 shares of J.B. Chemicals at ₹1639.18 per share
Torrent Pharmaceuticals has acquired 1,317 equity shares of J.B. Chemicals & Pharmaceuticals Limited on December 5th, 2025. The acquisition was made through an open offer at a price of ₹1639.18 per equity share. This acquisition is in accordance with SEBI regulations regarding substantial acquisition of shares and takeovers. Investors should note this strategic move as it could potentially impact Torrent Pharma's future growth and market position.
Key Highlights
Acquired 1,317 equity shares of J.B. Chemicals
Acquisition price of ₹1639.18 per share
Acquisition date: December 5th, 2025
💼 Action for Investors
Investors should monitor Torrent Pharma's future announcements and financial performance to assess the impact of this acquisition. Consider reviewing JB Chemicals' performance as well.